Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

NCT04854928 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: LTX-109 gel, 3%
DRUG: Placebo gel

Sponsor

Pharma Holdings AS

Collaborators

[object Object]